A randomized study of interferon-α versus interferon-α and low-dose arabinosyl cytosine in chronic myeloid leukemia

Blood

Volumn 99, Issue 5, 2002, Pages 1527-1535

  Baccarani, Michele ^a,b,c,d   Rosti, Gianantonio ^a,b,c,d   De Vivo, Antonio ^a,b,c,d   Bonifazi, Francesca ^a,b,c,d   Russo, Domenico ^a,b,c,d   Martinelli, Giovanni ^a,b,c,d   Testoni, Nicoletta ^a,b,c,d   Amabile, Marilina ^a,b,c,d   Fiacchini, Mauro ^a,b,c,d   Montefusco, Enrico ^a,b,c,d   Saglio, Giuseppe ^a,b,c,d   Tura, Sante ^a,b,c,d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTARABINE; RECOMBINANT ALPHA2A INTERFERON;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PATIENT COMPLIANCE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0036493582     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.5.1527     Document Type: Article

References (40)

1. A in chronic myelogenous leukemia
2. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia
3. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia
4. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia
5. UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response
6. A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase
7. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy
8. Interferon alfa versus chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized trials
9. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology
10. New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia
11. Monitoring treatment and survival in chronic myeloid leukemia
12. Treatment of chronic myelogenous leukemia: Current status and investigational options
13. A prospective comparison of α-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia: Clinical and cytogenetic results at 2 years in 322 patients
14. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-α2b for chronic myeloid leukemia
15. Interferon-α and hydroxyurea in early chronic myeloid leukemia: A comparative analysis of the Italian and the German chronic myeloid leukemia trials with interferon-α
16. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
17. Treatment of Philadelphia chromosome-positive early phase chronic myelogenous leukemia with daily doses of interferon alpha and low dose cytarabine
18. Efficacy and toxicity of IFN-α2b combined with cytarabine in chronic myelogenous leukemia
19. Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
20. Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukemia
21. Autologous stem cell transplantation in chronic myeloid leukemia: A single center experience
22. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase
23. Autografting with Philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia
24. A prospective study of α-interferon and autologous bone marrow transplantation in chronic myeloid leukemia
25. Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia
26. Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia
27. Cytogenetic remissions in chronic myelogenous leukemia using interferon alpha-2a and hydroxyurea with or without low-dose cytosine arabinoside
28. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-α and low-dose cytarabine
29. Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine
30. Prognostic discrimination in good risk chronic granulocytic leukemia
31. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa
32. Nonparametric estimation for incomplete observations
33. Clinical pharmacology of low-dose cytosine arabinoside
34. Chronic myeloid leukemia
35. Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival. Cancer and Leukemia Group B Study 8583
36. Interferon alfa as primary treatment of chronic myeloid leukemia: Long-term follow up of 71 patients observed in a single center
37. Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: Long-term results of a multicenter phase-II study
38. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
39. Molecular pathogenesis of chronic myeloid leukemia: Implications for new therapeutic strategies
40. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia